Metabolism of α-thujone in human hepatic preparations in vitro

Xenobiotica

Volumn 41, Issue 2, 2011, Pages 101-111

  Abass, Khaled ^a   Reponen, Petri ^a   Mattila, Sampo ^a   Pelkonen, Olavi ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

Cytochrome P450; Hepatic clearance; in vitro in vivo extrapolation; LC MS; Thujone

Indexed keywords

2 HYDROXYTHUJONE; 4 HYDROXYTHUJONE; 7 HYDROXYTHUJONE; ABSINTHOL; CARVACROL; CYSTEINE; CYTOCHROME P450; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; DRUG METABOLITE; GLUTATHIONE; UNCLASSIFIED DRUG;

ARTICLE; BIOTRANSFORMATION; CATALYSIS; CONTROLLED STUDY; DRUG CONJUGATION; DRUG METABOLISM; HUMAN; HUMAN TISSUE; HYDROXYLATION; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER HOMOGENATE; LIVER MICROSOME; MASS SPECTROMETRY;

ADULT; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; ISOENZYMES; KINETICS; LIVER; MALE; MASS SPECTROMETRY; MICROSOMES, LIVER; MIDDLE AGED; MONOTERPENES; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 78651377521     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2010.528066     Document Type: Article

References (32)

1. Abass K, Reponen P, Jalonen J, Pelkonen O. (2007a). In vitro metabolism and interaction of profenofos by human, mouse and rat liver preparations. Pestic Biochem Physiol 87:238-247. (Pubitemid 46176041)
2. Abass K, Reponen P, Turpeinen M, Jalonen J, Pelkonen O. (2007b). Characterization of diuron N-demethylation by mammalian hepatic microsomes and cDNA-expressed human cytochrome P450 enzymes. Drug Metab Dispos 35:1634-1641.
3. Abelö A, Andersson TB, Antonsson M, Naudot AK, Skånberg I, Weidolf L. (2000). Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 28:966-972. (Pubitemid 30612617)
4. Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, Tucker GT, Rostami-Hodjegan A. (2007). Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 8:33-45.
5. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
6. Burke MD, Prough RA, Mayer RT. (1977). Characteristics of a microsomal cytochrome P-448-mediated reaction. Ethoxyresorufn O-de-ethylation. Drug Metab Dispos 5:1-8.
7. Dettling A, Grass H, Schuf A, Skopp G, Strohbeck-Kuehner P, Hafner HT. (2004). Absinthe: attention performance and mood under the infuence of thujone. J Stud Alcohol 65:573-581.
8. Greenlee WF, Poland A. (1978). An improved assay of 7-ethoxycoumarin O-deethylase activity: induction of hepatic enzyme activity in C57BL/6J and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2,3,7,8- tetrachlorodibenzo-p-dioxin. J Pharmacol Exp Ter 205:596-605.
9. He X, de Montellano PR. (2004). Radical rebound mechanism in cytochrome P-450-catalyzed hydroxylation of the multifaceted radical clocks alpha-and beta-thujone. J Biol Chem 279:39479-39484.
10. Heinemann A, Wischhusen F, Püschel K, Rogiers X. (1999). Standard liver volume in the Caucasian population. Liver Transpl Surg 5:366-368.
11. Höld KM, Sirisoma NS, Ikeda T, Narahashi T, Casida JE. (2000). Alpha-thujone (the active component of absinthe): gamma-aminobutyric acid type A receptor modulation and metabolic detoxifcation. Proc Natl Acad Sci USA 97:3826-3831.
12. Höld KM, Sirisoma NS, Casida JE. (2001). Detoxifcation of alpha-and beta-Tujones (the active ingredients of absinthe): site specifcity and species diferences in cytochrome P450 oxidation in vitro and in vivo. Chem Res Toxicol 14:589-595.
13. Ishida T, Toyota M, Asakawa Y. (1989). Terpenoid biotransformation in mammals. V. Metabolism of (+)-citronellal, (+-)-7-hydroxycitronellal, citral, (-)-perillaldehyde, (-)-myrtenal, cuminaldehyde, thujone, and (+-)-carvone in rabbits. Xenobiotica 19:843-855.
14. Jiang Y He X, Ortiz de Montellano PR. (2006). Radical intermediates in the catalytic oxidation of hydrocarbons by bacterial and human cytochrome P450 enzymes. Biochemistry 45:533-542.
15. Jiang Y, Ortiz de Montellano PR. (2009). Cooperative efects on radical recombination in CYP3A4-catalyzed oxidation of the radical clock beta-thujone. Chembiochem 10:650-653.
16. Kronbach T, Mathys D, Gut J, Catin T, Meyer UA. (1987). High-performance liquid chromatographic assays for bufuralol 1-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purifed cytochrome P-450 isozymes of human liver. Anal Biochem 162:24-32.
17. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. (1989). Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89-96.
18. Kröner L, Padosch SA, Lachenmeier DW, Madea B. (2005). Untersuchungen zur forensischen relevanz thujonhaltiger spirituosen unter besonderer berücksichtigung toxikologisch-analytischer aspekte. Blutalkohol 42:263-271.
19. Lachenmeier DW, Walch SG, Padosch SA, Kröner LU (2006). Absinthe-a review. Crit Rev Food Sci Nutr 46:365-377.
20. Li XQ, Björkman A, Andersson TB, Ridderström M, Masimirembwa CM. (2002). Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high afnity and turnover enzyme-specifc probe substrate. J Pharmacol Exp Ter 300:399-407.
21. Pelkonen O, Kaltiala EH, Larmi TK, Kärki NT (1974). Cytochrome P-450-linked monooxygenase system and drug-induced spectral interactions in human liver microsomes. Chem Biol Interact 9:205-216.
22. Pelkonen O, Turpeinen M. (2007). In vitro-in vivo extrapolation of hepatic clearance: biological tools, scaling factors, model assumptions and correct concentrations. Xenobiotica 37:1066-1089.
23. Peter R, Böcker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. (1990). Hydroxylation of chlorzoxazone as a specifc probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 3:566-573.
24. Raunio H, Valtonen J, Honkakoski P, Lang MA, Ståhlberg M, Kairaluoma MA, Rautio A, Pasanen M, Pelkonen O. (1990). Immunochemical detection of human liver cytochrome P450 forms related to phenobarbital-inducible forms in the mouse. Biochem Pharmacol 40:2503-2509.
25. Raunio H, Rautio A, Gullstén H, Pelkonen O. (2001). Polymorphisms of CYP2A6 and its practical consequences. Br J Clin Pharmacol 52:357-363.
26. Rostami-Hodjegan A, Tucker GT. (2007). Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140-148.
27. Scientifc Committee on Food. (2002). Opinion of the Scientifc Committee on Food.on Tujone (http://ec.europa.eu/food/fs/sc/scf/out162-en.pdf).
28. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfeld GM, Miners JO, Birkett DJ, Goldstein JA. (1996). Te role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341-349.
29. Tolonen A, Petsalo A, Turpeinen M, Uusitalo J, Pelkonen O. (2007). In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies. J Mass Spectrom 42:960-966.
30. Turpeinen M, Nieminen R, Juntunen T, Taavitsainen P, Raunio H, Pelkonen O. (2004). Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab Dispos 32:626-631.
31. Turpeinen M, Uusitalo J, Jouko U, Jalonen J, Jorma J, Pelkonen O, Olavi P. (2005). Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur J Pharm Sci 24:123-132.
32. Zanger UM, Turpeinen M, Klein K, Schwab M. (2008). Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392:1093-1108.